FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:1851-1862 November 2, 2006 Number 18 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Levine, M. N. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The National Epirubicin Adjuvant Trial (NEAT) and the BR9601 trial examined the efficacy of anthracyclines in the adjuvant treatment of early breast cancer.

Methods In NEAT, we compared four cycles of epirubicin followed by four cycles of cyclophosphamide, methotrexate, and fluorouracil (CMF) with six cycles of CMF alone. In the BR9601 trial, we compared four cycles of epirubicin followed by four cycles of CMF, with eight cycles of CMF alone every 3 weeks. The primary end points were relapse-free and overall survival. The secondary end points were adverse effects, dose intensity, and quality of life.

Results The two trials included 2391 women with early breast cancer; the median follow-up was 48 months. Relapse-free and overall survival rates were significantly higher in the epirubicin–CMF groups than in the CMF-alone groups (2-year relapse-free survival, 91% vs. 85%; 5-year relapse-free survival, 76% vs. 69%; 2-year overall survival, 95% vs. 92%; 5-year overall survival, 82% vs. 75%; P<0.001 by the log-rank test for all comparisons). Hazard ratios for relapse (or death without relapse) (0.69; 95% confidence interval [CI], 0.58 to 0.82; P<0.001) and death from any cause (0.67; 95% CI, 0.55 to 0.82; P<0.001) favored epirubicin plus CMF over CMF alone. Independent prognostic factors were nodal status, tumor grade, tumor size, and estrogen-receptor status (P<0.001 for all four factors) and the presence or absence of vascular or lymphatic invasion (P=0.01). These factors did not significantly interact with the effect of epirubicin plus CMF. The overall incidence of adverse effects was significantly higher with epirubicin plus CMF than with CMF alone but did not significantly affect the delivered-dose intensity or the quality of life.

Conclusions Epirubicin plus CMF is superior to CMF alone as adjuvant treatment for early breast cancer. (ClinicalTrials.gov number, NCT00003577 [ClinicalTrials.gov] .)

Source Information

From the Cancer Research U.K. Clinical Trials Unit, Institute for Cancer Studies, Birmingham (C.J.P., L.H., J.A.D., S.B., D.W.R.); Addenbrookes Hospital, Cambridge (H.M.E., K.M.); Radiotherapy and Oncology Centre, Walsgrave Hospital, Coventry (R.J.G.); Cancer Centre, Queen Elizabeth Hospital, Birmingham (D.A.S., I.N.F.); Royal Shrewsbury Hospital, Shropshire (R.K.A.); Staffordshire Oncology Centre, Staffordshire (A.M.B.); Clatterbridge Hospital, Merseyside (S.M.O.); Airedale General Hospital, Yorkshire (S.M.C.); Royal South Hampshire Hospital, Southampton (P.S.); St. George's Hospital, London (J.L.M.); City Hospital, Birmingham (A.S.); St. James's University Hospital, Leeds (P.H.); Peterborough District Hospital, Cambridgeshire (K.M.); Scottish Cancer Therapy Network, Edinburgh (L.F.); Swansea Cancer Centre, Wales (R.C.F.L.); and Bradford Royal Infirmary, Bradford (C.J.T.) — all in the United Kingdom.

Address reprint requests to Dr. Poole at the Cancer Research U.K. Clinical Trials Unit, Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TT, United Kingdom, or at poolecj{at}aol.com.

Full Text of this Article

This article has been cited by other articles:

• Gianni, L., Norton, L., Wolmark, N., Suter, T. M., Bonadonna, G., Hortobagyi, G. N. (2009). Role of Anthracyclines in the Treatment of Early Breast Cancer. JCO 27: 4798-4808 [Abstract] [Full Text]  
• Pritchard, K. I. (2009). Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?. JCO 27: 3875-3876 [Full Text]  
• Gianni, L., Baselga, J., Eiermann, W., Porta, V. G., Semiglazov, V., Lluch, A., Zambetti, M., Sabadell, D., Raab, G., Cussac, A. L., Bozhok, A., Martinez-Agullo, A., Greco, M., Byakhov, M., Lopez, J. J. L., Mansutti, M., Valagussa, P., Bonadonna, G. (2009). Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer. JCO 27: 2474-2481 [Abstract] [Full Text]  
• Gianni, L., Valagussa, P. (2009). Anthracyclines and Early Breast Cancer: The End of an Era?. JCO 27: 1155-1157 [Full Text]  
• McGlynn, L. M., Kirkegaard, T., Edwards, J., Tovey, S., Cameron, D., Twelves, C., Bartlett, J. M.S., Cooke, T. G. (2009). Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients. Clin. Cancer Res. 15: 1487-1495 [Abstract] [Full Text]  
• Bartlett, J. M.S., Munro, A., Cameron, D. A., Thomas, J., Prescott, R., Twelves, C. J. (2008). Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial. JCO 26: 5027-5035 [Abstract] [Full Text]  
• Di Leo, A., Moretti, E. (2008). Anthracyclines: The First Generation of Cytotoxic Targeted Agents? A Possible Dream. JCO 26: 5011-5013 [Full Text]  
• Raffaghello, L., Lee, C., Safdie, F. M., Wei, M., Madia, F., Bianchi, G., Longo, V. D. (2008). From the Cover: Reactive Oxygen Species Special Feature: Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc. Natl. Acad. Sci. USA 105: 8215-8220 [Abstract] [Full Text]  
• Wolowacz, S. E., Cameron, D. A., Tate, H. C., Bagust, A. (2008). Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis. JCO 26: 925-933 [Abstract] [Full Text]  
• Tran, L.-P. P., Grabinski, J. L. (2008). Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux. Journal of Pharmacy Practice 21: 46-56 [Abstract]  
• Francis, P., Crown, J., Di Leo, A., Buyse, M., Balil, A., Andersson, M., Nordenskjold, B., Lang, I., Jakesz, R., Vorobiof, D., Gutierrez, J., van Hazel, G., Dolci, S., Jamin, S., Bendahmane, B., Gelber, R. D., Goldhirsch, A., Castiglione-Gertsch, M., Piccart-Gebhart, M., On behalf of the BIG 02-98 Collaborative Group, (2008). Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial. JNCI J Natl Cancer Inst 100: 121-133 [Abstract] [Full Text]  
• Bartlett, J. M.S., Ellis, I. O., Dowsett, M., Mallon, E. A., Cameron, D. A., Johnston, S., Hall, E., A'Hern, R., Peckitt, C., Bliss, J. M., Johnson, L., Barrett-Lee, P., Ellis, P. (2007). Human Epidermal Growth Factor Receptor 2 Status Correlates With Lymph Node Involvement in Patients With Estrogen Receptor (ER) Negative, but With Grade in Those With ER-Positive Early-Stage Breast Cancer Suitable for Cytotoxic Chemotherapy. JCO 25: 4423-4430 [Abstract] [Full Text]  
• Verma, S., Clemons, M. (2007). First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy. The Oncologist 12: 785-797 [Abstract] [Full Text]  
• Costa, S.-D., Bischoff, J. (2007). Adjuvant Therapy for Early Breast Cancer. NEJM 356: 1268-1269 [Full Text]  
• (2006). Epirubicin improves classic chemotherapy for early breast cancer. BMJ 333: 1014-1014 [Full Text]  
• (2006). Anthracycline-Based Adjuvant Chemotherapy for Early-Stage Breast Cancer. JWatch Oncology and Hematology 2006: 2-2 [Full Text]  
• Levine, M. N., Whelan, T. (2006). Adjuvant Chemotherapy for Breast Cancer -- 30 Years Later. NEJM 355: 1920-1922 [Full Text]